Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Mechanisms of Retrovirus-induced Cancers01:51

Mechanisms of Retrovirus-induced Cancers

Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Estimating the Effectiveness of COVID-19 Mitigation Policy in Rhode Island.

Rhode Island medical journal (2013)·2024
Same author

Challenges in evaluating the use of viral sequence data to identify HIV transmission networks for public health.

Statistical communications in infectious diseases·2021
Same author

Clinical Outcomes of Free, Public Skin Cancer Screening Events, Rhode Island, 2015-2019.

Rhode Island medical journal (2013)·2021
Same author

57% decline in Rhode Island invasive breast cancer mortality between 1987 and 2017: mammography predominates in preventing mortality.

Breast cancer research and treatment·2020
Same author

Suboptimal Opioid Prescribing: A Practice Change Project.

Rhode Island medical journal (2013)·2018
Same author

Rhode Island tick-borne disease surveillance summary 2012-2013.

Rhode Island medical journal (2013)·2014
Same journal

1776: Medical Care During the Revolutionary War.

Rhode Island medical journal (2013)·2026
Same journal

New HIV Diagnoses Among Hispanic/Latino Men Who Have Sex with Men, 2010-2024, Rhode Island.

Rhode Island medical journal (2013)·2026
Same journal

Improving Health Equity Training with an Integrated Simulation-Based Curriculum.

Rhode Island medical journal (2013)·2026
Same journal

Interpreter Use in an Academic Pediatric Hospital.

Rhode Island medical journal (2013)·2026
Same journal

Impact of Acute, Major Infrastructure Failure on Emergency Medical Service Transport Times in Rhode Island.

Rhode Island medical journal (2013)·2026
Same journal

Developing an Automated Text Message Program in the Emergency Department.

Rhode Island medical journal (2013)·2026
See all related articles

Related Experiment Video

Updated: May 11, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Metachronous cancer.

Arvin S Glicksman1, John P Fulton

  • 1Director of the Rhode Island Cancer Council, Inc., and professor emeritus of radiation medicine of the Warren Alpert Medical School of Brown University.

Rhode Island Medical Journal (2013)
|May 4, 2013
PubMed
Summary
This summary is machine-generated.

Cancer survivors face a growing risk of developing a second primary cancer, with lung, colon, breast, and prostate cancers being most common. Early detection and support are crucial for improving outcomes.

Keywords:
cancermetachronous cancersurvivorship

More Related Videos

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion
05:23

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Published on: July 7, 2023

Related Experiment Videos

Last Updated: May 11, 2026

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion
05:23

Tracking Tumor Cell Dissemination from Lung Metastases Using Photoconversion

Published on: July 7, 2023

Area of Science:

  • Oncology
  • Cancer Epidemiology
  • Public Health

Background:

  • Cancer survivorship is increasing due to medical advancements.
  • Metachronous cancers (subsequent primary tumors) are a growing concern for long-term cancer patients.
  • Understanding the patterns of metachronous cancers is vital for improving patient care.

Purpose of the Study:

  • To analyze the incidence and trends of metachronous cancers in Rhode Island.
  • To identify common sites and time intervals for second and higher-order primary tumors.
  • To explore the implications of metachronous cancers for cancer survivorship and intervention strategies.

Main Methods:

  • Utilized data from the Rhode Island Cancer Registry (1987-2009).
  • Calculated age-adjusted, sequence-specific incidence rates for all cancers.
  • Determined site-specific incidence rates for common second and higher-order primary malignant neoplasms.

Main Results:

  • The proportion of sequence two and higher cancers increased from 11.5% to 20.3% in males and 12.8% to 20.7% in females.
  • Lung, colon, breast, and prostate cancers accounted for 54.3% of all sequence two and higher diagnoses.
  • Average interval between first and second cancers was 6.5 years for men and 4.8 years for women.

Conclusions:

  • Approximately one in four cancer survivors develop a second primary cancer.
  • Significant intervals between cancers suggest opportunities for targeted prevention and screening interventions.
  • Robust social support networks are essential for individuals navigating the challenges of multiple cancer diagnoses.